Sumitomo Dainippon Pharma Annual Report 2017
94/102

Note: The “Other Business” category incorporates operations not included in reportable segments, including food ingredients, food additives, chemical product materials, veterinary drugs, diagnostics and other products.1) Outline of reportable segmentsThe Group’s reportable segments are the components of the Group whose operating results are regularly reviewed by the board of directors to make decisions about resources to be allocated to the segment and assess their performance, and for which discrete nancial information is available. The Group assesses its pharmaceutical business performance according to the reportable segments of the Group which consist of the following four segments: Japan, North America, China, Other regions.2) Method of calculating sales and income/loss, assets, liabilities and other items by reportable segmentAccounting method for business segment reporting is the same as presented in Note 2 “Summary of Signicant Accounting Policies.” Income by reportable segment is calculated based on operating income before R&D costs. Intersegment sales and transfers are calculated based on current market prices. Assets and liabilities by reportable segment are not shown because such information is not used to make decisions regarding resource allocation and performance measurement.3) Information on sales, income/loss and other items by reportable segmentSegment information for the Group for the years ended March 31, 2017 and 2016 were as follows:16. SEGMENT INFORMATIONMillions of yenJapanNorth AmericaChinaOther RegionsSubtotalOther BusinessTotal¥ 140,84850140,89838,3074,237—¥ 197,889—197,88983,2893,5725,560¥ 17,624—17,6246,743327—¥ 11,567—11,5672,804431—¥ 367,92850367,978131,1438,5675,560¥ 43,7117543,7862,40799—¥ 411,639125411,764133,5508,6665,5602017Net sales Sales to customers Intersegment sales and transfers Total Income of segment Others Depreciation and amortization Amortization of GoodwillMillions of yenJapanNorth AmericaChinaOther RegionsSubtotalOther BusinessTotal¥ 146,492142146,63441,5354,353—¥ 184,869—184,86965,1553,7355,980¥ 18,374—18,3747,992421—¥ 11,189—11,1892,446422—¥ 360,924142361,066117,1288,9315,980¥ 42,2827742,3591,821152—¥ 403,206219403,425118,9499,0835,9802016Net sales Sales to customers Intersegment sales and transfers Total Income of segmentOthers Depreciation and amortization Amortization of GoodwillNotes to Consolidated Financial StatementsSumitomo Dainippon Pharma Co., Ltd. and Consolidated SubsidiariesYears Ended March 31, 2017 and 2016Financial SectionSumitomo Dainippon Pharma Co., Ltd. Annual Report 201793

元のページ  ../index.html#94

このブックを見る